ERBB2 and breast cancer: Intriguingly, the role of ITGB1 differed in various BC gene-editing models [68], with total blocking occurring in the PyVmT-induced mammary tumor model as opposed to ITGB1 knock-down in ErbB2 tumors that failed to stop breast carcinogenesis and only delayed it by 30 days [68].